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a b s t r a c t
Aims: It is of interest to understand how insulin therapy currently evolves in clinical
practice, in the years after starting insulin in people with type 2 diabetes. We aimed to
describe this evolution prospectively over 4 years, to assist health care planning.
Methods: People who had started any insulin were identified from 12 countries on three con-
tinents. Baseline, then yearly follow-up, data were extracted from clinical records over 4 years.
Results: Of the 2999 eligible people, 2272 were followed over 4 years. When starting insulin,
mean (SD) duration of diabetes was 10.6 (7.8) years, HbA1c 9.5 (2.0)% (80 [22] mmol/mol) and
BMI 29.3 (6.3) kg/m2. Initial insulin therapy was basal 52%, premix 23%, mealtime + basal
14%, mealtime 8% and other 3%; at 4 years, 30%, 25%, 33%, 2% and 5%, respectively, with 5%
not on insulin. Insulin dose was 20.2 U/day at the start and 45.8 U/day at year 4. There were
1258 people (55%) on their original regimen at 4 years, and this percentage differed according
to baseline insulin regimen. HbA1c change was 2.0 (2.2)% (22 [24] mmol/mol) and was
similar by final insulin regimen. Hypoglycaemia prevalence was <20% in years 1–4. Body
weight change was mostly in year 1, and was very variable, mean +2.7 (7.5) kg at year 4.
Conclusion: Different insulin regimens were started in people with differing characteristics,
and they evolved differently; insulin dose, hypoglycaemia and body weight change were
diverse and largely independent of regimen.
# 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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0168-8227/# 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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When people with type 2 diabetes on metformin and other oral
therapies can no longer attain the recommended glucose
control targets, insulin therapy is generally started. Recom-
mendations as to insulin type vary [1–3]. Some authorities
endorse both basal and premix approaches, and others place
more emphasis on basal insulin; mealtime insulin alone is
used on occasion, or in a comprehensive mealtime + basal
regimen even from the time of starting insulin [4]. Random-
ized clinical trials have provided evidence on the relative
efficacy of insulin regimens [5,6], but these trials were
conducted in people and clinical environments that may
not be representative of those in routine clinical practice. Little
is known of the impact of starting insulin for outcomes of
importance to people with diabetes, such as change in insulin
regimen, insulin dose, hypoglycaemia and weight change,
with data available only for single countries [7–9], or in less or
recently developed nations [4], or particular insulins [10,11],
often with follow-up of 1 year or less [4,7,8].
Analyses based on non-interventional observational stud-
ies may overcome some of the challenges of generalizability
inherent to randomized trials and such studies provide a
bridge from randomized trials towards more routine settings
[4]. The Cardiovascular Risk Evaluation in people with Type 2
Diabetes on Insulin Therapy (CREDIT) study, an international
4-year, non-interventional, longitudinal study, was designed
to evaluate prospectively, in routine clinical practice in a large
number of clinical centres, the relationship between blood
glucose control and cardiovascular events in people beginning
any insulin. Further, this study aimed to describe current
medical practice in people with type 2 diabetes using insulin.
Here we report the evolution of insulin use, associated blood
glucose-related outcomes and effects on body weight and
hypoglycaemia, over 4 years. Cardiovascular outcomes and
the factors associated with them will be reported separately.
2. Methods
The CREDIT study design, site/participant selection process
and participant baseline characteristics have been reported
previously [12]. Briefly, the study was conducted in 314 centres
in 12 countries – Canada, Japan and 10 in Europe – between
December 2006 and May 2012. Ethical approval was obtained
for all study sites. Conduct of the study adhered to standards
of data collection for clinical trials, according to the Declara-
tion of Helsinki. Prior written informed consent was obtained
from all participants.
Men and women with type 2 diabetes, age >40 years, were
eligible if they had started any insulin regimen >1 month and
<12 months prior to study entry and had an HbA1c
measurement within 3 months of beginning insulin. Data at* Corresponding author at: Institute for Cellular Medicine – Diabe-
tes, The Medical School, Framlington Place, Newcastle upon Tyne
NE2 4HH, United Kingdom. Tel.: +44 191 208 7154/8643; fax: +44 191
208 0723.
E-mail address: philip.home@ncl.ac.uk (P.D. Home).the start of insulin were collected retrospectively from clinical
records. As CREDIT was a non-interventional study, there was
no fixed study visit schedule, and insulin choice, dosage,
titration, funding and concomitant oral agent therapy were
according to usual local practice. Data were gathered from
routine clinical practice, with the physicians asked to report
updated data every 6 months. Data at ‘4 years’ represent that
ascertained 42–54 months after beginning insulin, and data for
1, 2 or 3 years were for 9–18, 18–30 and 30–42 months,
respectively.
Glucose control was assessed by HbA1c, fasting plasma
glucose (FPG) and postprandial plasma glucose (PPPG). HbA1c
is presented in both National Glycohemoglobin Standardiza-
tion Program and International Federation of Clinical Chem-
istry units [13,14]. FPG and PPPG are reported as either
laboratory or self-monitored glucose values. Documented
symptomatic hypoglycaemia, nocturnal hypoglycaemia and
severe hypoglycaemia were assessed over the 6 months prior
to the follow-up date. Body weight change, other glucose-
lowering medications and changes of insulin regimen were
also assessed.
2.1. Statistical methods
Analyses were performed with SAS software, version 9.1 (Cary,
NC, USA). All data are reported and analyzed using descriptive
statistics. Data on insulin regimens, other glucose-lowering
medications, blood glucose control and body weight are
presented by insulin regimen when starting insulin. For 4-
year and change from baseline data, data for insulin dose,
blood glucose control, body weight and hypoglycaemia are
presented by insulin regimen at 4 years. Initial and yearly data
for insulin dose, HbA1c, FPG, PPPG and body weight change are
presented for the entire population. Updated HbA1c, defined
as the average of all values from 1 month after starting insulin
to 4 years of follow-up, was used to report results by baseline
insulin regimen; all other results for HbA1c are reported by
year interval. Because of the likelihood of some degree of
allocation bias, comparative statistical testing was not
performed, avoiding the danger of spurious statistically
significant findings with the large numbers of people studied.
3. Results
There were 3060 participants included, with 2999 having valid
eligibility criteria (Supplementary, Fig. S1). When starting
insulin, the eligible population was 49% female, with an
average (standard deviation [SD]) age of 61 (10) years, body
mass index of 29.3 (6.3) kg/m2, duration of diabetes of 11 (8)
years and HbA1c of 9.5 (2.0)% (80 [22] mmol/mol). Seventy
percent had at least one microvascular disease, 34% had a
macrovascular disease and 69% were previously diagnosed
with hypertension. In the 4-year data interval, data were
available for 2272 (75.8%) participants.
Supplementary Fig. S1 related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.diabres.
2015.01.030.
Table 1 – Glucose-lowering medications, glycaemic control and body weight when starting insulin by starting insulin
regimen.
Starting insulin regimen
Basal Mealtime + basal Mealtime Premix Other
N = 2999; n (%) 1558 (52) 420 (14.0) 226 (7.5) 692 (23.1) 103 (3.4)
Other glucose-lowering drugs, n (%)
None 176 (11.3) 274 (65.2) 125 (55.3) 264 (38.2) 69 (67.0)
1 1382 (88.7) 146 (34.8) 101 (44.7) 428 (61.8) 34 (33.0)
1 583 (37.4) 107 (25.5) 44 (19.5) 241 (34.8) 23 (22.3)
2 665 (42.7) 37 (8.8) 48 (21.2) 134 (19.4) 10 (9.7)
3 134 (8.6) 2 (0.5) 9 (4.0) 53 (7.7) 1 (1.0)
Metformin 993 (63.7) 105 (25.0) 69 (30.5) 291 (42.1) 23 (22.3)
Sulfonylurea 983 (63.1) 49 (11.7) 49 (21.7) 214 (30.9) 12 (11.7)
Thiazolidinedione 145 (9.3) 13 (3.0) 17 (7.5) 77 (11.1) 8 (7.8)
Glinides 119 (7.6) 3 (0.7) 10 (4.4) 27 (3.9) 1 (1.0)
Alpha-glucosidase inhibitor 69 (4.4) 17 (4.0) 22 (9.7) 60 (8.7) 2 (1.9)
GLP-1 receptor agonist 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
DPP-4 inhibitor 2 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
HbA1c, % unit 9.2 (1.8) 10.1 (2.1) 9.5 (2.0) 9.8 (2.0) 9.2 (1.9)
mmol/mol 77 (20) 87 (23) 80 (22) 84 (22) 77 (21)
FPG, mg/dl 201 (56) 227 (68) 180 (64) 211 (69) 206 (63)
mmol/l 11.2 (3.1) 12.6 (3.8) 10.0 (3.6) 11.7 (3.8) 11.4 (3.5)
PPPG, mg/dl 239 (69) 280 (80) 276 (102) 266 (78) 257 (79)
mmol/l 13.3 (3.8) 15.6 (4.5) 15.3 (5.7) 14.8 (4.3) 14.3 (4.4)
Body weight, kg 83.1 (17.8) 75.2 (18.5) 69.2 (17.3) 78.2 (19.1) 73.4 (14.8)
Mean (SD) or n (%).
DPP-4, dipeptidylpeptidase-4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide-1; PPPG, postprandial plasma glucose; SD, standard
deviation.
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Of the 2999 participants starting insulin, 52.0% started on a
basal insulin, 14.0% on mealtime + basal, 7.5% on mealtime,
23.1% on premix and 3.4% on other insulin (premixed
insulin + basal and/or mealtime insulin) (Table 1). For the
2272 participants with 4-year data, the distribution of the
starting insulin regimens was similar to that for all eligible
participants (Fig. 1). At 4 years, 605 (52.0%) of the 1163
participants who started on basal insulin were on basal
insulin, 515 (44.3%) moved to other regimens and 43 (3.7%)
stopped insulin (Fig. 1). Sixty-six participants on other regi-
mens changed to basal insulin, so that in all 671 (29.5% of
participants with 4-year data) were on basal insulin at 4 years
(Fig. 1). For the 331 participants who started on mealtime +
basal insulin, 222 (67.1%) were on mealtime + basal insulin at 4
years, 83 (25.0%) moved to other regimens and 26 (7.9%)
stopped insulin. There were 519 participants who changed to
mealtime + basal insulin, for a total of 741 (32.6%) on the
regimen at 4 years (Fig. 1). Of the 536 participants who started
on premix insulin, 362 (67.5%) were on premix at 4 years, 148
(27.6%) moved to other regimens and 26 (4.9%) stopped insulin
(Fig. 1). However, 210 participants changed to premix, so that
in all, 572 (25.2%) were on premix at 4 years.
Only 33 (18.2%) of the 181 participants who started on
mealtime insulin were on mealtime insulin at 4 years, while
126 (69.6%) moved to other insulin regimens and 22 (12.2%)
stopped insulin (Fig. 1). Twenty-one participants moved to
mealtime insulin for a total of 54 (2.4%) on the regimen at 4
years. Thirty-six (59.0%) of the 61 participants who started on
other insulin were on other insulin at 4 years, while 22 (36.1%)
moved to other insulins and 3 (4.9%) stopped insulin. Seventy-eight participants moved to other insulin for a total of 114
(5.0%) on the regimen at 4 years.
A total of 120 participants (5.3%) from all of the regimens
had stopped insulin at 4 years. In all, 1258 (55.4%) of the 2272
participants with 4-year data were on the same starting
regimen at 4 years.
3.2. Evolution of other glucose-lowering medications
Of the eligible participants starting insulin, other glucose-
lowering medication(s) were taken by 88.7% starting on basal
insulin, 34.8% on mealtime + basal insulin, 44.7% on meal-
time insulin, 61.8% on premix and 33.0% on other insulin
(Table 1). The largest percentage taking two other medica-
tions was for those starting a basal insulin (43%), while the
largest percentage (67%) of those taking no other glucose-
lowering medication was for the other insulin grouping
(Table 1). When analyzed by insulin regimen at 4 years, 88.4%
of those on basal insulin, 46.6% on mealtime + basal insulin,
44.4% on mealtime insulin, 58.2% on premix, 46.5% on other
insulin and 86.7% of those who stopped insulin were taking at
least one other glucose-lowering medication at 4 years
(Table 2). The largest group of those on basal insulin at 4
years were those taking one other glucose-lowering medica-
tion (43%). For other regimens, the largest group was people
taking no other glucose-lowering medication (range 42–56%,
Table 2).
Metformin and sulfonylureas were the predominant
glucose-lowering medications taken when starting insulin;
the frequencies of other medications ranged from 0% to 12%
across regimens (Table 1). Metformin was taken by 63.7% of
those starting on basal insulin, 25.0% starting on mealtime + -
Fig. 1 – Change in insulin regimen over 4 years for those with data at baseline and 4 years (N = 2272). Horizontal arrows
represent the movement of participants from one regimen to another at 4 years, with the number and percentage of
participants moving from the initial regimen shown above the arrow. Vertical arrows denote the movement of participants
on a regimen when starting insulin to the same regimen at 4 years. The number and percentage shown intersecting the
vertical arrows are participants who were on the same regimen at the start and at 4 years.
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22.3% on other insulin, while sulfonylureas were taken by
63.1%, 11.7%, 21.7%, 30.9% and 11.7%, respectively (Table 1).
When analyzed by insulin regimen at 4 years, 65.1% of those
on basal insulin, 39.0% on mealtime + basal insulin, 33.3% on
mealtime insulin, 45.6% on premix, 33.3% on other insulin and
53.3% of those who stopped insulin were taking metformin,
while 45.2%, 7.6%, 16.7%, 13.6%, 8.8% and 45.0%, respectively,
were taking sulfonylureas (Table 2).
Overall for participants starting insulin, 30.3% were not
taking any other glucose-lowering medications, increasing to
36.1% at 4 years. The use of sulfonylureas declined from 43.6%
at the start of insulin to 22.4% at 4 years, though for those on
basal insulin, 45% still used sulfonylureas. Thiazolidinedione
use also declined (8.7% vs. 4.5%). Metformin use remained
relatively constant (49.4% vs. 48.7%). The use of GLP-1 receptor
agonists and DPP-4 inhibitors increased from 0.1% to 2.4%
and 5.4%, respectively.
3.3. Evolution of insulin dose
For the entire population, the mean (SD) daily dose of insulin
upon starting was 20.2 (14.9) U/day and increased to 45.8(31.7) U/day at 4 years (Fig. 2). By insulin regimen at 4 years, the
starting dose ranged from 15.7 (11.0) U/day for those ending on
basal insulin to 23.3 (17.0) U/day for those on mealtime + basal
insulin (Table 2). The dose at 4 years ranged from 27.2
(41.2) U/day on mealtime insulin to 59.8 (34.5) U/day on
mealtime + basal insulin. The starting dose for participants
who were not taking insulin at 4 years was 17.2 (13.4) U/day.
3.4. Blood glucose control
Overall mean (SD) HbA1c declined from 9.5 [2.0]% (80
(21) mmol/mol) when starting insulin to 7.6 [1.3]% (60
(14) mmol/mol) at 4 years (median (7.3%) [56 mmol/mol]
(Fig. 2). The change in HbA1c at 4 years was 2.0 [2.2]% (–22
(24) mmol/mol). FPG declined from 11.6 (3.8) mmol/l at the
start to 7.7 (2.4) mmol/l at 4 years (Fig. 2). PPPG declined from
14.3 (4.6) mmol/l to 9.4 (3.2) mmol/l at 4 years (Fig. 2). The
change at 4 years was 3.8 (4.0) mmol/l for FPG and 5.1
(4.9) mmol/l for PPPG. Most of the decline in HbA1c (20
[23] mmol/mol (1.8 [2.1]%)), FPG (3.5 [3.9] mmol/l) and PPPG
(4.6 [4.9] mmol/l) occurred in the first year (Fig. 2).
The people started on mealtime + basal or premix regimens
had average HbA1c at baseline rather higher than those
Table 2 – Glucose-lowering medications, insulin dose, glycaemic control, body weight and hypoglycaemia at 4 years, by
insulin regimen at 4 years.
Insulin regimen at 4 years
Basal Mealtime +
basal
Mealtime Premix Other No insulin
N = 2272; n (%) 671 (29.5) 741 (32.6) 54 (2.4) 572 (25.2) 114 (5.0) 120 (5.3)
Other glucose-lowering drugs, n (%)
None 78 (11.6) 396 (53.4) 30 (55.6) 239 (41.8) 61 (53.5) 16 (13.3)
1 593 (88.4) 345 (46.6) 24 (44.4) 333 (58.2) 53 (46.5) 104 (86.7)
1 290 (43.2) 278 (37.5) 16 (29.6) 231 (40.4) 36 (31.6) 34 (28.3)
2 250 (37.3) 56 (7.6) 5 (9.3) 79 (13.8) 16 (14.0) 35 (29.2)
3 53 (7.9) 11 (1.5) 3 (5.6) 23 (4.0) 1 (0.9) 35 (29.2)
Metformin 437 (65.1) 289 (39.0) 18 (33.3) 261 (45.6) 38 (33.3) 64 (53.3)
Sulfonylurea 303 (45.2) 56 (7.6) 9 (16.7) 78 (13.6) 10 (8.8) 54 (45.0)
Thiazolidinedione 29 (4.3) 20 (2.7) 2 (3.7) 29 (5.1) 7 (6.1) 15 (12.5)
Glinides 85 (12.7) 13 (1.8) 3 (5.6) 25 (4.4) 5 (4.4) 15 (12.5)
Alpha-glucosidase
inhibitor
26 (3.9) 23 (3.1) 2 (3.7) 49 (8.6) 8 (7.0) 10 (8.3)
GLP-1 receptor agonist 19 (2.8) 5 (0.7) 0 (0.0) 2 (0.3) 0 (0.0) 29 (24.2)
DPP-4 inhibitor 58 (8.6) 18 (2.4) 1 (1.9) 17 (3.0) 3 (2.6) 26 (21.7)
Insulin dose
Start, U/day 15.7 (11.0) 23.3 (17.0) 18.4 (16.3) 20.9 (14.1) 22.8 (17.9) 17.2 (13.4)
4 year, U/day 32.6 (22.2) 59.8 (34.5) 27.2 (41.2) 44.7 (29.6) 46.2 (27.6) –
Start, U/kg/day 0.2 (0.1) 0.3 (0.2) 0.3 (0.2) 0.3 (0.2) 0.3 (0.2) 0.2 (0.1)
4 year, U/kg/day 0.4 (0.2) 0.7 (0.3) 0.3 (0.3) 0.5 (0.3) 0.6 (0.2) –
HbA1c, % units/mmol/mol
Start 9.2 (1.8)/77 (20) 9.6 (1.9)/81 (21) 9.1 (1.7)/76 (13) 9.8 (2.0)/84 (22) 9.7 (2.1)/83 (23) 9.8 (1.9)/84 (21)
4-year 7.3 (1.1)/56 (12) 7.7 (1.3)/61 (14) 7.3 (1.3)/56 (14) 7.7 (1.3) 61 (14) 7.6 (1.3)/60 (14) 7.3 (1.4)/56 (15)
Change 1.9 (2.0)/20 (22) 1.9 (2.2)/20 (24) 1.8 (2.2)/20 (24) 2.1 (2.2)/23 (24) 2.1 (2.4)/23 (26) 2.5 (2.3)/27 (25)
FPG, mg/dl/mmol/l
Start 203 (58)/11.3 (3.2) 208 (64)/11.5 (3.5) 178 (60)/9.9 (3.3) 209 (63)/11.6 (3.5) 208 (67)/11.6 (3.7) 207 (69)/11.5 (3.8)
4 year 130 (38)/7.2 (2.1) 142 (44)/7.9 (2.4) 152 (52)/8.5 (2.9) 140 (44)/7.8 (2.5) 147 (43)/8.2 (2.4) 139 (65)/7.7 (3.6)
Change 73 (64)/4.1 (3.6) 66 (73)/3.7 (4.1) 20 (74)/1.1 (4.1) 69 (72)/3.8 (4.0) 63 (75)/3.5 (4.2) 65 (89)/3.6 (4.9)
PPPG, mg/dl/mmol/l
Start 238 (71)/13.2 (3.9) 258 (76)/14.4 (4.2) 245 (98)/13.6 (5.4) 271 (83)/15.1 (4.6) 264 (83)/14.7 (4.6) 285 (88)/15.9 (4.9)
4 year 161 (48)/8.9 (2.7) 170 (55)/9.4 (3.1) 169 (50)/9.4 (2.8) 176 (68)/9.8 (3.8) 163 (56)/9.0 (3.1) 172 (63)/9.6 (3.5)
Change 79 (78)/4.4 (4.3) 92 (88)/5.1 (4.9) 85 (103)/4.7 (5.7) 98 (93)/5.4 (5.1) 102 (104)/5.7 (5.8) 115 (100)/6.4 (5.6)
Body weight, kg
Start 83.3 (18.4) 79.9 (17.3) 75.0 (24.8) 76.3 (18.2) 74.1 (18.5) 75.4 (21.9)
4 year 84.6 (18.3) 84.0 (17.8) 76.9 (25.9) 79.8 (18.7) 77.0 (17.9) 75.7 (22.2)
Change 1.1 (7.8) 4.2 (7.6) 0.6 (7.6) 3.4 (6.5) 3.4 (6.0) 2.2 (7.7)
Hypoglycaemia last 6 months – any documented
People with
1 event, n (%)
100 (14.9) 138 (18.6) 8 (14.8) 109 (19.1) 18 (15.8) 2 (2.5)
Any event rate
(events/person)
1.22 (4.67) 1.03 (3.62) 0.94 (4.25) 1.02 (3.57) 0.78 (2.21) 0.33 (2.95)
Nocturnal rate
(events/person)
0.23 (1.15) 0.25 (1.27) 0.28 (2.06) 0.18 (1.11) 0.21 (0.92) 0.00 (0.00)
Hypoglycaemia last 6 months – severe
People with
1 event, n (%)
22 (3.3) 19 (2.6) 3 (5.6) 2 (0.3) 0 (0.0) 0 (0.0)
Severe event rate
(events/person)
0.15 (1.02) 0.09 (0.91) 0.22 (1.37) 0.0 (0.06) 0.00 (0.00) 0.00 (0.00)
Nocturnal rate
(events/person)
0.03 (0.27) 0.02 (0.21) 0.17 (1.09) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Values are n (%) or mean (SD).
DPP-4, dipeptidylpeptidase-4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide-1; PPPG, postprandial plasma glucose; SD, standard
deviation.
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over the 4 years, updated HbA1c, which averaged 59
(11) mmol/mol (7.6 [1.0]%), appeared little different accordingto insulin regimen at the start, basal 61 (11) mmol/mol (7.7
[1.0]%), mealtime + basal 58 (12) mmol/mol (7.5 [1.1]%), meal-
time only 57 (11) mmol/mol (7.4 [1.0]%) and premix 62
Fig. 2 – Evolution of HbA1c (A), fasting plasma glucose (B), postprandial plasma glucose (C), insulin dose (D), change in body
weight (baseline 79.6 (18.9) kg) (E) over 4 years, with proportion of people having at least one documented hypoglycaemia
episode in the 6 months before each year interval (F). Data (A)–(E) are mean (standard deviation).
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 8 ( 2 0 1 5 ) 3 5 0 – 3 5 9 355(12) mmol/mol (7.8 [1.1]%). Also by insulin regimen at start
HbA1c to a target of <7.0% (<53 mmol/mol) was achieved at
1 and 4 years by basal: 31% and 34%, mealtime + basal: 42% and
42%, mealtime only: 45% and 44%, premix: 28% and 32% and no
insulin 36% and 36%.
By insulin regimen at 4 years, the baseline mean HbA1c
ranged from 9.1% (76 mmol/mol) for those ending on basal
insulin to 9.8% (84 mmol/mol) for those ending on premix or
no insulin (Table 2). At 4 years, mean HbA1c ranged from 7.3%
(56 mmol/mol) for those on basal alone, mealtime alone or no
insulin to 7.7% (61 mmol/mol) on premix or mealtime + basal
insulin. By final insulin regimen, the mean change from
baseline was similar for the different insulin regimens (Table 2).Mean FPG at the start of insulin therapy ranged from
9.9 mmol/l for those on mealtime insulin at 4 years to
11.6 mmol/l on premix (Table 2). At 4 years, mean FPG ranged
from 7.2 mmol/l on basal insulin to 8.4 mmol/l on mealtime
insulin, with mean change from 1.1 mmol/l on mealtime
insulin to 4.1 mmol/l on basal insulin (Table 2). Mean PPPG at
the start of insulin therapy ranged from 13.2 mmol/l for those
on basal insulin at 4 years to 15.9 mmol/l for those who
stopped insulin (Table 2). At 4 years, mean PPPG ranged from
8.9 mmol/l for those on basal insulin to 9.8 mmol/l on premix,
with mean change from 4.4 mmol/l with basal insulin to
6.4 mmol/l for those who stopped insulin (Table 2).
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Body weight at 4 years increased for the entire population by
2.7 (7.5) kg, with most of the gain occurring in the first year (1.9
[5.2] kg) (Fig. 2). Initial mean (SD) body weight ranged from 74.1
(18.5) kg for those on other insulin at 4 years to 83.3 (18.4) kg on
basal insulin (Table 2). Body weight at 4 years ranged from 75.7
(22.2) kg for those on no insulin to 84.6 (18.3) kg on basal
insulin. The change ranged from 2.2 (7.7) kg for those on no
insulin to +4.2 (7.6) kg on mealtime + basal insulin (Table 2).
In the entire population, the percentage of participants
who experienced at least one hypoglycaemia episode in the
last 6 months of year 1 was 18.5%; year 2, 18.3%; year 3, 16.1%
and year 4, 16.6% (Fig. 2). The mean (SD) number of
documented symptomatic hypoglycaemia episodes per per-
son during the last 6 months of year 1 were 1.1 (4.6); year 2, 1.0
(4.8); year 3, 0.9 (3.2) and year 4, 1.03 (3.88), while the number of
documented nocturnal symptomatic hypoglycaemia episodes
per person were for the last 6 months of year 1, 0.1 (0.9); year 2,
0.1 (0.9); year 3, 0.1 (0.8) and year 4, 0.21 (1.17). The proportion
of participants who reported at least one severe hypoglycae-
mia episode in the last 6 months of year 1 was 1.9%; year 2,
1.7%; year 3, 2.0% and year 4, 2.0%.
The percentage of participants with at least one docu-
mented hypoglycaemia episode in the last 6 months before the
4-year follow-up ranged from 14.8% for those on mealtime
insulin alone to 19.1% for those on premix (Table 2). The
number of documented symptomatic and nocturnal hypogly-
caemia episodes per person was also similar across insulin
regimens. The percentage of participants who reported at least
one severe hypoglycaemic episode during that same period
ranged from none on other insulin or no insulin to 5.6% on
mealtime insulin (Table 2). The average number of events per
person for severe hypoglycaemia in the last 6 months before 4
years ranged from 0.00 (0.00) on other insulin or no insulin to
0.22 (1.37) with mealtime insulin.
Even on basal insulin at 4 years, with 45% using a
sulfonylurea, only 10 people experienced severe hypoglycae-
mia, and the rate was the same (3.3%) in sulfonylurea and non-
sulfonylurea users. In basal insulin users at 4 years the
proportion of people having documented symptomatic hypo-
glycaemia in the last 6 months was independent of sulfonyl-
urea use or non-use (14.9% for both), as was event rate and
nocturnal event rate (data not shown). Use of sulfonylureas at
4 years in all other insulin groups was too small (except no
insulin) for rates of documented symptomatic hypoglycaemia
to be meaningful.
4. Discussion
The CREDIT study, conceived both to examine the perfor-
mance of different insulin regimens over 4 years and to
examine relationships of those regimens to cardiovascular
outcomes (to be reported separately), offers a unique
opportunity to study how insulin regimens, and health
outcomes related to them, evolve in routine clinical practice.
This is of importance for people with diabetes starting insulin
and for the health professionals advising them, but data arealso provided for health care planning and health economic
analysis with descriptive information on body weight change,
hypoglycaemia and insulin dose.
The study was performed in nations with established
economic development (Canada, Europe, Japan), and there
were no restrictions as to insulin types or regimens that could
be used, and no protocol-determined interventions or assess-
ments other than those performed in normal clinical practice.
Other studies that have looked at people starting insulin have
generally been restricted to particular insulin types, such as
insulin analogues, have been single centre, and/or have
been shorter term, though some have addressed therapy
performance in developing/recently prosperous countries
[4,9–11,15]. Additionally, some longer-term randomized
control data are available, but the levels of intervention
were unusually high throughout, with the explicit intention
of influencing health outcomes [5,16].
We have noted previously, in discussing factors influencing
choice of first insulin in this population, that overall blood
glucose control was very poor at the time of starting insulin
[12]. It is possible that this reflects the finding of poor glucose
control in circumstances that lead to insulin being started,
such as hospitalization or after specialist referral, rather than
being typical of ambulatory care; but it is consistent with
findings of the A1chieve study, with the UK database studies,
and with US data [4,8,17,18]. While numerically the HbA1c
levels before starting insulin were highest for the initial
insulin regimens that combined a mealtime and a basal
insulin (including premix), and while this might reflect
physicians’ perception that people in poorer control required
more comprehensive insulin replacement, because this is a
non-randomized study the observation does not lend itself to
statistical comparison [19].
Despite poor control at baseline, or perhaps because of it,
response to all insulin regimens was good at 1 year and
through to 4 years, with mean HbA1c reductions of 1.8–2.1%
units (20–23 mmol/mol) in those remaining on insulin, and no
mean change between 1 and 4 years. The high baseline values
are consistent with large initial HbA1c reductions even for
non-insulin therapies [20–22]. These large initial falls in HbA1c
have been reported in other observational studies, and
attributed as much to educational/behavioural change as to
the insulin itself [4], though in clinical database studies, poorer
glucose is reported [8], and is perhaps associated with greater
persistence of initial therapy [8,23,24]. The average levels
achieved were not to internationally endorsed levels: <7.0%
(<53 mmol/mol), but the population studied had a long duration
of diabetes, with significant comorbidities. It is likely that in line
with modern guidelines, individual targets were higher in a
sizeable proportion of the study participants [1,2,25].
The stability of glucose control in routine diabetes care over
4 years is impressive, given that islet b-cell function
deteriorates with time [26], and that insulin therapy in the
UK Prospective Diabetes Study (UKPDS) showed continuing
deterioration of HbA1c [27]. However, it is known that, given
attention, glucose control need not deteriorate with time, even
late in the course of diabetes, as demonstrated in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) study for
both the standard and the intensive control groups [28]. It is
however clear in CREDIT that both the initial improvement in
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continuing increases in insulin dose. Barriers to maintenance
of glucose control on insulin are often cited as weight gain and
hypoglycaemia, but in our study weight gain was very modest
in those continuing to be treated with mealtime or basal
insulin alone, and overall was about 1 kg a year in those
requiring some form of combined therapy including premix.
This is in contrast to the UK study, with weight gain of around
3 kg in 12 months despite worse glucose control [8], perhaps
emphasizing that lifestyle input had a greater impact in our
multinational study. Predictors of body weight change in the
first year of the CREDIT study have been published [29].
Hypoglycaemia did not increase after the first year,
continuing to affect fewer than 20% of people over the last 6
months of the study, with a population rate of approximately
one episode per person. Severe hypoglycaemia (requiring
assistance) was uncommon, and thus the estimates of its
frequency uncertain, but our data suggest a rate of about 0.2
episodes per year on average, assuming ascertainment is
satisfactory. It is not clear what proportion of this severe
hypoglycaemia might require paramedical or medical assis-
tance, glucagon, or association with an adrenergic reaction.
The rate is lower than that reported by a UK study group, but
the authors of that smaller study are noted for a special
interest in hypoglycaemia and may have been following
unusual populations of people at higher risk [30]. However,
low rates of severe hypoglycaemia have been reported in
populations starting insulin even in short-term observational
studies [4,31], and the proportion of people in CREDIT suffering
any event is consistent with the Treating To Target in Type 2
diabetes (4T) trial [5]. Some people, especially in the basal
insulin only group, remained on sulfonylureas throughout.
That their prevalence of hypoglycaemia in the last 6 months
was identical to non-sulfonylurea users can probably be
attributed to clinical care, the previous 3.5 years allowing
opportunity for stopping any medication that was a problem.
This might also account for the low percentage of sulfonylurea
users in those taking premix or a mealtime + basal regimen at
the end of study, or it might be that position statements
advising against this were being followed [2]. Alternatively in
people with reasonable and stable blood glucose control
(mean HbA1c at 4 years 7.2%), use of modern sulfonylureas in
combination with basal insulin might not add to the
sulfonylurea risk.
It is to some extent encouraging and reassuring that in
routine care, clinicians are able to help people with diabetes
and to use insulin to good effect. However, the standard
deviations of insulin dose and body weight change, as well as
for hypoglycaemia, reveals that there are individuals who
have more problems on insulin, and these problems probably
influence general clinical perceptions to some degree. Thus
the standard deviation for weight change at 4 years was 6–
7.8 kg, while the wide standard deviation for 4-year insulin
dose suggests more than one in 20 individuals were using
>120 U/day. In the circumstance where only one in six
individuals had a hypoglycaemic event in 6 months, the
average rate is 1 event, the group of affected individuals is
experiencing approximately one event per month, and a small
minority probably a higher rate. Thus while the overallexperience of insulin therapy over 4 years is good, this is
not to deny that a small proportion of people have problems.
By either initial or final insulin regimen, outcomes were
fairly similar, with the exception of body weight, as noted
above. However, only half of the people initially on basal
insulin, and about two-thirds on multiple injection therapy or
premix, were still on their first regimen by the end of study. As
might be expected, the majority starting basal who moved to a
combined regimen did so by adding mealtime insulin; a much
smaller group went to a premix regimen. Those starting on
basal insulin alone tended to be heavier, and avoidance of any
mealtime insulin may have influenced physicians’ choice of
insulin, but it is also possible that confounding of the data is
occurring due to concurrence of heavier populations in
regions where use of basal regimens has become popular.
Those who moved away from a mealtime + basal regimen
went almost equally to basal alone or premix, but in this
observational study we cannot know if these changes are
driven by desire for regimen simplification, high rates of
hypoglycaemia with mealtime insulin, or because the
complex regimen was not necessary in those individuals.
However, as a result, the best glucose control levels were for
those remaining on single insulin regimens, with medians of
54 mmol/mol (7.1%) and 52 mmol/mol (6.9%) for basal and
mealtime alone, respectively.
The largest proportion moving from premix go to a
mealtime + basal regimen, but again whether this is driven
by poor blood glucose control, desire for more flexible eating or
a problem with hypoglycaemia is unknown. However, the
observation that overall 50% of people did change insulin
regimen implies that physicians took an active approach to
insulin therapy once started, as noted for dose titration above.
Clearly the temptation merely to adjust insulin dose was
avoided, and seemingly by the diversity of changes, attempts
were generally made to match insulin regimens to the
individuals’ evolving biomedical needs and personal desires.
A small proportion of people (5%) came off insulin therapy
altogether at some point over the 4 years. As these people had
a greater fall in HbA1c than those who stayed on insulin, and a
fall in body weight, it seems their cessation of insulin therapy
was in response to lifestyle and biomedical changes, rather
than dissatisfaction with insulin. Consistent with this, the
starting insulin dose of this group was not low, baseline oral
agent number was high and baseline body weight was not low.
Use of oral agents showed some unexpected character-
istics. Metformin use was not usual in combination with
insulin, and, while it increased during the study, it never
exceeded two-thirds of the population. While our relatively
older study population would include a significant percentage
with some renal impairment, the data more likely reflect the
belief of prior decades that insulin therapy should be used
alone. The increase in metformin use over the 4 years of study
is then consistent with wider adoption of more recent
guideline advice [1–3]. More easily explained is the higher
use of sulfonylureas with basal insulin at the start of therapy,
though also to some extent with premix, and the fall in
number of users with time, particularly on the latter regimen.
However, the extent to which these changes are driven by
experience of hypoglycaemia or weight gain, or guidelines,
cannot be known. Other glucose-lowering therapies were little
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and incretin therapies are merely consistent with safety
concerns and license changes over the period of study.
Our study has other limitations. As noted, it was restricted
to economically developed nations. Furthermore, even be-
tween and within these countries, clinical habits vary
markedly. This can lead to loss of generalizability, but also
bias, for example, by the higher initial use of thiazolidine-
diones in Canada, or the greater use of premix and lower body
mass index in Japan. Relying on local routine measurements
would account for some of our apparent loss to follow-up, as
the individual participants might not have had a clinical
assessment in the time windows used for our yearly data
collection. We also assume that laboratory measurements are
comparable across countries and sites, something that has
been a problem, in particular with HbA1c [14].
Nevertheless, these data are perhaps the best available to
inform further clinical guidelines about the use of insulin
therapy, for planning and for economic assessments, and to
guide people with diabetes and their advisors about what to
expect. We would also conclude that despite insulin being
started at levels of glucose control much worse than generally
advised, the results overall are respectable, if not perfect, in
terms of achieved metabolic control, tolerability and safety,
particularly when taken in the context of the Outcome Reduction
with Initial Glargine Intervention (ORIGIN) study, undertaken in
a very different cohort of people with diabetes [16]. Most
encouraging perhaps is the evidence that clinicians in routine
practice are taking adequate steps to change insulin dose and
regimens to avoid deterioration of blood glucose control with
time, and actively changing and sometimes even stopping
insulin therapy appropriately in response to other needs.
In conclusion, in regular clinical practice across a group of
developed nations, clinicians and people with diabetes
achieve modestly encouraging results in regards of glucose
control, weight change, and hypoglycaemia when starting a
range of insulin regimens. Glucose control does not deterio-
rate over 4 years, this being attributable to evolution in insulin
regimens in over half the people starting insulin, as well as
insulin dose titration.
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